Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 1-year average of 138.63%, near the low end of its 1-year range (0.00%–693.16%).
100.00% below its 12-month average of 138.63%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 693.16%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
138.63%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Nautilus Biotechnolgy, Inc.
Market Cap
$225.88M
Gross Margin
0.00%
TTM Avg
138.63%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$231.25M
Gross Margin
-24677.94%
TTM Avg
-13289.35%
3Y Avg
-6830.59%
5Y Avg
-4553.73%
Market Cap
$231.69M
Gross Margin
71.12%
TTM Avg
81.41%
3Y Avg
85.88%
5Y Avg
90.00%
Market Cap
$233.62M
Gross Margin
99.39%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
Market Cap
$231.62M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$234.90M
Gross Margin
68.57%
TTM Avg
73.00%
3Y Avg
80.96%
5Y Avg
81.80%
Market Cap
$234.98M
Gross Margin
54.88%
TTM Avg
55.31%
3Y Avg
58.01%
5Y Avg
59.27%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $225.88M | 0.00% | 138.63% | 0.00% | 0.00% |
| Biodesix, Inc. (BDSX)vs › | $228.27M | 82.50% | 79.64% | 73.94% | 65.24% |
| Vogenx Inc. (VOGX)vs › | $231.18M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $231.25M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | 71.12% | 81.41% | 85.88% | 90.00% |
| BioAge Labs Inc. (BIOA)vs › | $233.62M | 99.39% | 50.00% | 25.00% | 25.00% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| SIGA Technologies, Inc. (SIGA)vs › | $234.90M | 68.57% | 73.00% | 80.96% | 81.80% |
| Utah Medical Products, Inc. (UTMD)vs › | $234.98M | 54.88% | 55.31% | 58.01% | 59.27% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.17M | 79.48% | 71.93% | 74.52% | 72.98% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 693.16% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
